Recent Research

Compiled for your convenience are the latest articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology. Articles are obtained from the National Library of Medicine’s MEDLINE database and date back to 2010.

Article Titlesort descending Original Publication Date Journal Bone Marrow Disease
Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going Feb 2014 Transl Med UniSa paroxysmal nocturnal hemoglobinuria (PNH)
Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy Apr 2014 Hematol Oncol myelodysplastic syndromes (MDS)
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia Mar 2014 Leuk Res myelodysplastic syndromes (MDS)
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy Feb 2017 Oncotarget myelodysplastic syndromes (MDS)
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study May 2014 Eur J Haematol myelodysplastic syndromes (MDS)
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution Sep 2014 Blood aplastic anemia
"Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution. Sep 2014 Blood aplastic anemia
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials Feb 2012 Leuk Lymphoma myelodysplastic syndromes (MDS)
5-Azacytidine for the treatment of myelodysplastic syndromes. Apr 2013 Expert Opin Pharmacother myelodysplastic syndromes (MDS)
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials Oct 2016 Leukemia myelodysplastic syndromes (MDS)